#DNA Sequencing Platforms Market size

[tamanna31]

mRNA Synthesis Raw Materials Market Size, Share, Growth, Analysis Forecast to 2030

mRNA Synthesis Raw Materials Industry Overview

The global mRNA synthesis raw materials market size was estimated at USD 1.72 billion in 2023 and is anticipated to grow at a CAGR of 2.85% from 2024 to 2030.

mRNA is synthesized by the process of transcription in the nucleus by using a template made up of a DNA nucleotide sequence. It includes various steps such as initiation, elongation, editing, and termination. mRNA synthesis has a broad range of applications in drug discovery, vaccine development, and the manufacturing of therapeutics. RNA-based vaccines have better immunogenicity, higher efficiency, and require short production time. The key factors driving the market growth include the growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research.

Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market

The COVID-19 pandemic created new opportunities for mRNA technology platforms with the introduction and widespread use of vaccines. Government agencies from several nations, research institutions, and numerous biotech and pharmaceutical companies are focusing on efficient and quick methods for the rapid detection of COVID-19. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA-based COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe.

The National Institute of Allergy & Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. It shows 94.1% efficacy in symptomatic prevention from COVID-19 and in December 2020, received emergency use authorization from the US Food & Drug Administration (US FDA) for widespread immunization of people. As a result, the usage of mRNA vaccines increased exponentially during the COVID-19 pandemic.

Recently, RNA centers have been established at numerous institutions to promote therapeutic uses of RNA, particularly in vitro transcribed (IVT) mRNA. These facilities include the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, the State University of New York, and the RNA Therapeutic Institute at the University of Massachusetts in the United States. Additionally, university spin-off businesses funded by significant venture capital infusions such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido have advanced the preclinical and clinical development of mRNA-based therapeutics. Hence, growing academic and industrial interest in mRNA technology is anticipated to increase the need for mRNA synthesis raw materials, thereby boosting market growth.

Furthermore, the simplicity to manufacture the mRNA vaccine is a key reason for the development of these vaccines. For instance, it is essential for DNA to enter the nucleus, and then it can be transcribed into mRNA. However, mRNA does not need to enter the nucleus to function as it initiates protein translation in the cytoplasm. Hence, this process makes the mRNA vaccine more efficient and simple to manufacture. In contrast to viral vectors and DNA, mRNAs do not insert into the genome but express the encoded protein instantaneously. Typical cellular processes can eliminate the mRNA since it doesn’t integrate into the host genome, thus eliminating any chance of infection or insertion mutation. In addition, the In Vitro Transcription (IVT) process readily synthesizes mRNA. The process is relatively inexpensive and can be quickly applied to a variety of therapies. Such advantages of mRNA vaccines are anticipated to drive the market during the study period.

Moreover, several operating players in the market and various research institutes are receiving funding for the development of novel mRNA therapeutics. For instance, in October 2022, the University of Columbia received USD 11.1 million in funding from the government of Canada to advance the mRNA vaccine technology. This funding aims to improve their efficacy, reduce the potential side effects of vaccines, and allow for a smaller vaccine dosage. Similarly, in December 2022, ExPLoRNA Therapeutics received USD 813,578 in funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. Therefore, rising funding for research is expected to increase the need for mRNA synthesis raw materials and fuel the market growth during the forecast period.

Additionally, the growing prevalence of chronic and infectious diseases is increasing the therapeutic application of mRNA technology. For instance, according to WHO, cancer is one of the leading causes of death worldwide, causing almost one in six deaths, while cardiovascular diseases lead to an estimated 17.9 million deaths each year. In addition, according to WHO, about 10 million people worldwide contracted tuberculosis in 2020 (1.1 million children, 5.6 million men, & 3.3 million women). Hence, scientists in industries and universities worldwide are finding novel and innovative ways to develop therapeutics using mRNA technology to prevent and treat disease. For instance, researchers at Penn Medicine are using the mRNA platform to create vaccines for several conditions such as cancer, treatment for food and environmental allergies, genetic diseases, and heart attack and stroke, among others.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global recombinant DNA technology market size was valued at USD 728.9 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030.

• The global DNA diagnostics market size was estimated at USD 10.64 billion in 2023 and is projected to grow at a CAGR of 4.51% from 2024 to 2030.

Key mRNA Synthesis Raw Materials Company Insights

The market players operating in the mRNA synthesis raw materials market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key mRNA Synthesis Raw Materials Companies:

The following are the leading companies in the mRNA synthesis raw materials market. These companies collectively hold the largest market share and dictate industry trends

F. Hoffmann-La Roche Ltd.

Jena Bioscience GmbH

Merck KGaA

Yeasen Biotechnology (Shanghai) Co., Ltd.

BOC Sciences

Thermo Fisher Scientific, Inc.

Maravai LifeSciences

New England Biolabs

Creative Biogene

HONGENE

Recent Developments

In April 2024, Telesis Bio Inc. announced its refocusing strategy to promote its innovative Gibson SOLA platform, targeting DNA and mRNA drug discovery. The company will also concentrate on enhancing its BioXp platform for mRNA synthesis, leveraging its distinct competitive advantage.

In February 2023, Life Edit Therapeutics Inc. and Moderna Inc. signed a collaboration agreement to discover and develop mRNA gene-editing therapies.

In January 2023, BioNTech and the UK Government signed a Strategic Partnership Agreement to help patients by advancing clinical trials for targeted mRNA immune therapies. To provide targeted cancer therapies to up to 10,000 patients by the end of 2030, through clinical trials or as approved treatments

Order a free sample PDF of the MRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.

[trendingreportz]

Metagenomics Market - Forecast(2024 - 2030)

Metagenomics Market Overview

Metagenomics Market size is estimated to reach $1.5 billion by 2027, growing at a CAGR of 16.2% during the forecast period 2022-2027. Metagenomics is the examination of genetic material reclaimed directly from environmental samples. The expansive field may also be specified as environmental genomics, eco-genomics or community genomics. Shotgun metagenomic sequencing is a comparatively novel environmental sequencing technique utilized to analyze thousands of organisms in parallel and completely sample all genes, offering acumen into community biodiversity and function. 16S rRNA gene sequencing is typically restricted to recognizing bacteria at the genus level (e.g. Bifidobacteria). De novo assembly has been a necessary instrument in current investigations in metagenomics viral analysis. Glycoside hydrolases (GHs) are amidst the industrially significant enzymes that are widely explored by way of metagenomics owing to their very great expedience and significance in food and additional industrial sectors. Whole-genome sequencing offers added information on the nature and localization of antimicrobial resistance factors and on their dissemination possibility by horizontal gene delivery, and on genes connecting to virulence and biological fitness. Interoperable data will play a principal role in the forthcoming utilization of whole genome sequencing and metagenomic data.

The COVID-19 pandemic is set to drive the Metagenomics Market owing to the extensive utilization of technologies like Metagenomics in pandemic hazard computations to detect the molecular alterations in pathogens at the time of their worldwide rise, which could help in the forecast of rising hotspots, populations at risk, and the pathogens under genetic evolution as per the research article issued in Future Science, 2021. The burgeoning interest of researchers in related new research fields like metatranscriptomics, metaproteomics, and metabolomics has inspired microbiologists to investigate related workflows` in conjunction with novel techniques like shotgun metagenomic sequencing and is set to propel the growth of the Metagenomics Market during the forecast period 2022-2027. This represents the Metagenomics Industry Outlook.

Report Coverage

The report: “Metagenomics Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Metagenomics Market.

By Product: Sequencing And Data Analytics Services, Kits And Reagents, Others. By Technology: Sequencing Driven, Function Driven. By Application: Human Health, Environmental, Others. By Geography: North America (the U.S, Canada, and Mexico), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), Europe (Germany, France, UK, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), and Rest Of The World (Middle East, Africa). 

Request Sample

Key Takeaways

Geographically, North America Metagenomics Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the existence of a soaring count of pharmaceutical and biotechnological firms developing new and effective metagenomic platforms in conjunction with novel techniques like shotgun metagenomic sequencing in the North American region.

Metagenomics Market growth is being driven by the technological advancements in DNA sequencing in conjunction with the development of novel techniques like shotgun metagenomic sequencing. However, the soaring cost of complete metagenomics is one of the major factors hampering the growth of the Metagenomics Market.

Metagenomics Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Metagenomics Market report. 

Metagenomics Market Segment Analysis – By Product:

The Metagenomics Market based on products can be further segmented into Sequencing And Data Analytics Services, Kits And Reagents, and Others. The Kits And Reagents Segment held the largest market share in 2021. This growth is owing to the considerable count of kits and reagents being introduced and utilized to back the increasing demand for library preparation workflows from research laboratories. The boost in the rate of application and the great infiltration in conjunction with the extensive application of shotgun metagenomic sequencing is further propelling the growth of the genome engineering segment.

Furthermore, the Sequencing And Data Analytics Services segment is estimated to grow with the fastest CAGR of 16.9% during the forecast period 2022-2027 owing to the accelerated and considerable cost minimization in next-generation sequencing which has productively expedited the growth of sequence-based metagenomics in conjunction with the soaring application of shotgun metagenomic sequencing.

Inquiry Before Buying

Metagenomics Market Segment Analysis – By Technology:

The Metagenomics Market based on technology can be further segmented into Sequencing Driven and Function Driven. The Sequencing Driven Segment held the largest market share in 2021. This growth is owing to the soaring application of this technology. The burgeoning acceptance of this technology may be ascribed to the onset of new bioinformatics-associated solutions, which make workflows easy and offers accelerated outcomes. shotgun metagenomic sequencing permits researchers to exhaustively sample all genes in all organisms existing in a given complex sample. Surging endeavors to keep up a standard database and increase in the count of metagenome samples accumulated at data repositories are further propelling the growth of this segment.

Furthermore, the Function Driven segment is estimated to grow with the fastest CAGR of 17.1% during the forecast period 2022-2027 owing to the increasing application of function-driven metagenomics for protein screening applied to antibiotic resistance and vitamin manufacture in conjunction with the proliferating application of shotgun metagenomic sequencing.

Metagenomics Market Segment Analysis – By Geography:

The Metagenomics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Metagenomics Market) held the largest share with 36% of the overall market in 2021. The growth of this region is owing to the surging spend on R&D. The extensive acceptance of metagenomic diagnostic, an expanding count of next-generation sequencing(NGS) based research endeavors in conjunction with increased application of shotgun metagenomic sequencing and the existence of key players like Illumina Inc., in the region are propelling the growth of the Metagenomics market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like consistent developments performed to build up the bioinformatics infrastructure and genomic landscape in nations like India and China. The considerable fluctuation in climate and environment in the region together with the heightening application of shotgun metagenomic sequencing is fuelling the progress of the Metagenomics market in the Asia-Pacific region.

Schedule a Call

Metagenomics Market Drivers

Increased Application Of Shotgun Metagenomic Sequencing Is Projected To Drive The Growth Of Metagenomics Market:

Shotgun metagenomic sequencing developed by Illumina Inc., permits researchers to completely sample all genes in all organisms existing in a given complex sample. The technique allows microbiologists to assess bacterial diversity and discover the profusion of microbes in different environments. Shotgun metagenomics also offers a means to investigate unculturable microorganisms that are otherwise hard or impossible to evaluate. Unlike capillary sequencing or PCR-based techniques, next-generation sequencing (NGS) permits researchers to sequence thousands of organisms in parallel. With the capability to integrate abundant samples in a single sequencing run and acquire high sequence coverage per sample, NGS-based metagenomic sequencing can discover very low abundance members of the microbial community that may be unnoticed or are too high-priced to recognize utilizing additional techniques. The surging application of shotgun metagenomic sequencing is fuelling the growth of the Metagenomics Market during the forecast period 2022-2027.

Benefits Of 16S rRNA Sequencing Are Expected To Boost The Demand Of Metagenomics:

16S rRNA Sequencing is a typical amplicon sequencing technique utilized to recognize and compare bacteria existing within a given sample. The prokaryotic 16S rRNA gene is almost 1500 bp long, with nine variable regions integrated between conserved regions. Variable regions of the 16S rRNA gene are generally utilized for the phylogenetic classification of genus or species in different microbial populations. An essential advantage of 16S rRNA Sequencing is that it offers an affordable method to recognize strains that may not be discovered utilizing conventional techniques. Unlike capillary sequencing or PCR-based techniques, next-generation sequencing (NGS) is a culture-free technique that allows investigation of the complete microbial community within a sample. 16S rRNA NGS permits microbiologists to accomplish genus-level sensitivity for metagenomic examinations of bacterial populations. The advantages of 16S rRNA Sequencing are driving the growth of the Metagenomics Market during the forecast period 2022-2027.

Metagenomics Market Challenges

Databases For Metagenomic Data Present Challenges To The Growth Of The Metagenomics Market:

Absorbing the sequence that will be produced by metagenomics projects will be demanding for the nucleic acid sequence data archive. Adding to the archiving challenge, it is evident that the community will need novel, secondary databases if the data are to be utilized efficiently. Only a specially-designed database will be able to provide constant storage and querying of the abundant metadata that metagenomic sequences require. The investigation of metagenomic sequences will need computational programs that are best provided in the context of a specially-designed database, for example, programs for the clustering of metagenomic sequence reads or for time-series analysis. And metagenomic data must be combined with data from distinct projects, like satellite data on ocean temperatures and time-series data on alterations in ocean salinity. This issue is hampering the growth of the Metagenomics Market.

Buy Now

Metagenomics Market Landscape:

Product launches, technological advancements, collaborations, mergers and acquisitions, financing in R&D activities, partnerships, and joint ventures are key strategies adopted by players in this Market. Metagenomics top 10 companies include:

Thermo Fisher Scientific, Inc.

QIAGEN

Illumina, Inc.

Promega Corporation

Novogene Co., Ltd.

Takara Bio, Inc

Oxford Nanopore Technologies

Arc Bio, LLC.

Eurofins Scientific

Zymo Research

Acquisitions/Product Launches:

In November 2021, QIAGEN declared the inclusion of StableScript™ to the OEM portfolio. The versatile reverse transcriptase is planned for application in one-step RT-qPCR and long-range RT-PCR and is accessible to order in bulk amounts. The launch of reverse transcriptases has permitted polymerase chain reaction (PCR) to be adapted to RNA and the establishment of cDNA libraries from mRNA.

In October 2021, QIAGEN N.V. declared the introduction and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis (TB) infection, to assist in accomplishing TB removal targets worldwide by boosting access to effortless and trustworthy TB testing, specifically in great burden countries, low-resource regions. A breakthrough in the battle against a pathogen estimated to be carried by over two billion people globally established on the proven QuantiFERON-TB Gold Plus technology, QIAreach® QuantiFERON®-TB is a portable instrument that allows the ultrasensitive digital discovery of TB infection with an end-to-end workflow that is clear and cost-efficient and raises access to trustworthy Interferon Gamma Release Assay (IGRA) testing. QIAGEN will target regions that encounter a huge burden of the ailment, and where procuring access to laboratory infrastructure and resources for testing is restricted.

In July 2021, QIAGEN N.V. declared the introduction of the Workflow Configurator, allowing researchers in the life sciences to effortlessly and speedily discover the best solutions to make their experiments perfect. Purchasers simply select their application, biological starting material, analyte, and analysis type. In seconds, the configurator arranges by way of hundreds of possible products to detect the most appropriate workflow and related products.

[heathcareforallworld]

Growth in the DNA Test for Dogs Market

The pet care industry has seen a significant surge in the demand for DNA testing for dogs, driven by the increasing interest of pet owners in understanding their pets' genetic backgrounds. DNA tests for dogs provide valuable insights into a dog's breed, ancestry, potential health risks, and genetic traits. This growing trend reflects the broader societal shift towards personalized healthcare and well-being, extending beyond humans to their pets. In this article, we will explore the current size and share of the DNA test for dogs market, key industry trends, and provide a forecast through 2032.

Market Size and Share

Dna Test for Dogs Market Size was estimated at 5.18 (USD Billion) in 2023. The Dna Test for Dogs Market Industry is expected to grow from 5.71(USD Billion) in 2024 to 12.5 (USD Billion) by 2032. The Dna Test for Dogs Market CAGR (growth rate) is expected to be around 10.29% during the forecast period (2024 - 2032). The increasing popularity of DNA tests for dogs is driven by a combination of factors, including rising pet ownership, growing awareness of pet health, and advancements in genetic testing technologies.

North America currently dominates the market, accounting for over 45% of the global market share. The high level of pet ownership, particularly in the United States, coupled with the availability of advanced veterinary services, has fueled the demand for dog DNA tests in this region. Europe follows as the second-largest market, driven by similar trends in pet ownership and the increasing focus on animal welfare. The Asia-Pacific region is expected to witness the fastest growth, with rising disposable incomes and an increasing number of pet owners fueling demand for DNA testing services for dogs.

Industry Trends

Rising Interest in Pet Genetics: One of the most significant trends driving the DNA test for dogs market is the growing interest in pet genetics among pet owners. Understanding a dog’s breed composition, genetic traits, and potential health risks has become a priority for many pet owners. This interest is often driven by the desire to provide better care and a healthier lifestyle for pets. DNA tests offer detailed insights into a dog's lineage, which can help owners make informed decisions about their pet's diet, exercise, and healthcare needs.

Advancements in Genetic Testing Technologies: Technological advancements in genetic testing have made DNA tests for dogs more accessible, affordable, and accurate. Next-generation sequencing (NGS) and microarray technologies have revolutionized the field, allowing for more comprehensive and detailed genetic analyses. These advancements have also led to the development of at-home DNA test kits, enabling pet owners to collect samples easily and receive results through online platforms. The convenience and accuracy of these tests are contributing to the market’s rapid growth.

Increasing Focus on Personalized Pet Care: The trend towards personalized care, which is already well-established in human healthcare, is now extending to pets. Pet owners are increasingly seeking customized solutions for their pets, including tailored diets, exercise regimens, and preventive healthcare based on genetic information. DNA tests provide valuable data that can inform personalized care plans, helping to improve the overall well-being of pets. This trend is expected to continue driving the demand for DNA tests for dogs in the coming years.

Growing Awareness of Canine Health Issues: There is a growing awareness among pet owners about the genetic health risks that dogs may face. Many hereditary conditions, such as hip dysplasia, heart disease, and certain types of cancer, can be identified through DNA testing. By understanding these risks early on, pet owners can take preventive measures or seek early intervention to manage potential health issues. This proactive approach to pet health is fueling the demand for DNA testing services.

Expansion of Veterinary Genomics: The veterinary field is increasingly incorporating genomics into its practice, with DNA testing becoming a standard part of comprehensive pet care. Veterinarians are using genetic data to make more informed diagnoses and treatment plans, particularly for breeds that are prone to specific genetic conditions. As veterinary genomics continues to evolve, it is expected to further drive the adoption of DNA tests for dogs, both in clinical settings and among pet owners.

Forecast to 2032

The DNA test for dogs market is poised for substantial growth over the next decade, driven by the aforementioned trends and an increasing focus on pet health and well-being.

Technological advancements will continue to play a key role in the market's expansion, with innovations in genetic testing technologies making DNA tests more comprehensive and accessible. The integration of artificial intelligence (AI) and machine learning into genetic analysis is expected to enhance the accuracy of predictions related to breed composition, health risks, and behavioral traits.

The Asia-Pacific region, in particular, is expected to see significant growth, driven by rising pet ownership and increasing awareness of pet health. As more pet owners in this region seek to understand their pets' genetic backgrounds, the demand for DNA testing services is likely to surge.

In addition, the market is expected to benefit from the increasing adoption of pet insurance, which often includes coverage for genetic testing. As more insurance providers recognize the value of DNA tests in preventive care, this could further boost the market's growth.

Conclusion

The DNA test for dogs’ market is rapidly growing, reflecting a broader trend towards personalized pet care and the increasing importance of genetic information in veterinary practice. With advancements in genetic testing technologies, rising pet ownership, and a growing focus on pet health, the market is expected to continue expanding over the next decade

[credenceresearchdotblog]

The nucleic acid isolation and purification market is indeed poised for substantial growth, with an anticipated value of USD 10.10 billion by 2032, reflecting a notable compound annual growth rate (CAGR) of 9.11% from USD 4.22 billion in 2023.The nucleic acid isolation and purification market is experiencing substantial growth, driven by advancements in biotechnology and increased research investments. This market encompasses a range of technologies and methodologies designed to extract and purify nucleic acids—DNA and RNA—from biological samples, which are essential for various applications in research, diagnostics, and therapeutics.

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-isolation-and-purification-market

Market Overview

Nucleic acid isolation and purification are critical processes in molecular biology, genomics, and personalized medicine. These processes enable scientists and researchers to study genetic material with high precision, paving the way for breakthroughs in disease understanding, drug development, and clinical diagnostics. The market for these technologies is expanding due to the growing demand for high-quality nucleic acid samples and the increasing prevalence of genetic disorders and cancer.

Market Drivers

1. Advancements in Biotechnology: The rapid progress in genomic technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), has spurred demand for reliable and efficient nucleic acid isolation and purification methods. These advancements are crucial for obtaining high-quality samples needed for accurate genomic analysis.

2. Rising Prevalence of Genetic Disorders: With the increasing incidence of genetic disorders and cancer, there is a heightened demand for genetic testing and personalized medicine. Accurate nucleic acid extraction and purification are essential for reliable diagnostic results and tailored treatment strategies.

3. Growing Research and Development Activities: Continuous research in fields like genomics, transcriptomics, and epigenomics requires advanced nucleic acid isolation and purification techniques. The proliferation of research activities in these areas contributes to the market's growth.

4. Technological Innovations: The development of automated systems and high-throughput platforms has enhanced the efficiency and scalability of nucleic acid isolation and purification processes. Innovations such as magnetic bead-based purification and microfluidic devices are driving market expansion.

Market Segmentation

The nucleic acid isolation and purification market can be segmented based on technology, product type, application, and end-user:

1. By Technology: Key technologies include column-based methods, magnetic bead-based methods, and gel electrophoresis. Magnetic bead-based methods are gaining popularity due to their high sensitivity and automation capabilities.

2. By Product Type: This segment includes kits, reagents, and instruments. Kits, which offer convenience and comprehensive solutions, dominate the market. Reagents and instruments are also essential components, with continuous innovation driving their adoption.

3. By Application: The primary applications are in research and development, diagnostics, and therapeutics. Research and development hold the largest share, driven by the need for genomic and transcriptomic studies.

4. By End-User: End-users include academic and research institutions, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. Academic and research institutions are significant contributors to the market due to their extensive research activities.

Regional Analysis

The nucleic acid isolation and purification market exhibits diverse trends across regions:

1. North America: The North American market is the largest, driven by the presence of major biotechnology firms, advanced research facilities, and significant investments in healthcare research.

2. Europe: Europe is also a major market, with a strong emphasis on research and development and a growing focus on personalized medicine. Countries like Germany and the UK are key contributors.

3. Asia-Pacific: The Asia-Pacific region is witnessing rapid growth due to increasing investments in research and development, expanding healthcare infrastructure, and a rising number of biotechnology firms. Countries like China and India are emerging as prominent players.

4. Latin America and the Middle East & Africa: These regions are experiencing steady growth, driven by improving healthcare infrastructure and increasing research activities.

Challenges and Future Outlook

Despite the market's growth, there are challenges such as high costs of advanced technologies and the need for skilled personnel. However, the ongoing development of cost-effective solutions and user-friendly platforms is expected to address these issues.

Looking ahead, the nucleic acid isolation and purification market is poised for continued growth, fueled by technological advancements, increasing research activities, and rising demand for genetic testing. The integration of artificial intelligence and machine learning in these processes is likely to further enhance efficiency and accuracy.

Key player:

QIAGEN N.V.

Thermo Fisher Scientific Inc.

Illumina Inc.

Danaher Corporation

Hoffmann La Roche Ltd

Merck KGaA

Agilent Technologies Inc.

Bio-Rad Laboratories

Takara Bio Inc.

Promega Corporation

New England Biolabs

Abcam plc.

PCR Biosystems

Segments:

By Product:

Kits

Reagents

Instruments

By Application:

Plasmid

DNA

RNA

By End User:

Pharmaceutical Companies

Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

By Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-isolation-and-purification-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[trendingrepots]

Bioinformatics Market - Forecast(2024 - 2030)

Bioinformatics Market Overview

Bioinformatics Market size was valued at $8.3 billion in 2020, growing at a CAGR of 12.4% during the forecast period 2021-2026. The recording, annotation, storage, analysis, and retrieval of nucleic acid sequence, protein sequence, and structural information are all covered by bioinformatics. Proteomics is the study of proteomes on a vast scale. A proteome is a collection of proteins made by a living creature, system, or biological milieu. Single nucleotide polymorphisms (SNPs) is a useful tool for determining the genetic basis of disease. In genome-wide association studies and fine-scale genetic mapping initiatives, these variants can be utilized as markers. Bioinformatics applications include molecular therapeutics, metabolomics, and proteomics, to name a few. It's also used in genetics and genomics research. The combination of biology and information technology is referred to as "bioinformatics." Computer software tools are used in bioinformatics to create, administer, and develop databases. Data warehousing, data mining, and communication networking all use it. Furthermore, it is frequently utilized in the field of medical research and medication development for the management of biological data. The worldwide Bioinformatics Market is predicted to develop owing to the high frequency of chronic diseases. According to the American Cancer Society, it was expected to have 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States year 2019.

Bioinformatics Market Report Coverage                                                                    

The report: “Bioinformatics Market – Forecast (2021-2026)”, by IndustryARC covers an in-depth analysis of the following segments of the Bioinformatics Market.

By Products & Services: Knowledge Management Tools, Bioinformatics Platforms, and Bioinformatics Services By Application: Genomics, Chemoinformatics & Drug Design, Proteomics, Transcriptomics, Metabolomics, and Others By Sector: Animal Biotechnology, Medical Biotechnology, Forensic Biotechnology, Plant Biotechnology, Environmental Biotechnology, Others By Geography: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina & Rest of South America) and Rest of the World (Middle East & Africa)

Key Takeaways

A single nucleotide polymorphism, or SNP (pronounced "snip"), is a difference in the DNA sequence at a single place between individuals. DNA is made up of a chain of four nucleotide bases: A, C, G, and T.

The rise in bioinformatics platform application can be ascribed to an increase in demand from life science companies for structural identification and customization. This, in turn, would aid in the development of drugs and the assessment of their therapeutic effects. Furthermore, as drug research and discovery become more efficient and safe, the demand for new tools in drug development grows. As a result, the Bioinformatics Market is likely to grow in the future.

A detailed analysis of the main players functioning in the Bioinformatics Market's Strengths, Weaknesses, and Opportunities will be provided in the report.

Bioinformatics Market Segment Analysis – By Products & Services:

Based on Products & Services, Bioinformatics Market is segmented into Knowledge Management Tools, Bioinformatics Platforms, and Bioinformatics Services. The Bioinformatics Platforms segment is accounted for the largest revenue market share in 2020 for Bioinformatics Market owing to an increase in platform applications and the demand for better tools in drug development. This trend is expected to continue during the projected period. The study of evolutionary history, development, and relationships among organisms using molecular sequence or structural data is known as molecular phylogenetics (DNA, RNA, or proteins). The Knowledge Management Tools segment is poised to grow with the fastest CAGR of 13.6% in the forecast period 2021-2026. Researchers utilize knowledge management technologies to deal with vast amounts of diverse data. This data comprises both experimental data and data acquired from publicly available repositories. Data management, data warehousing, data mining, and information retrieval are all functions of knowledge management technologies. By comparing them to available databases, these functions aid in understanding the structure of genes and proteins, as well as the implications of mutations.

Bioinformatics Market Segment Analysis – By Sector:

Based on Sector, Bioinformatics Market is segmented into Animal Biotechnology, Medical Biotechnology, Forensic Biotechnology, Plant Biotechnology, Environmental Biotechnology, Others. In 2020, the medical biotechnology segment accounted for the largest revenue market share for Bioinformatics Market. The use of bioinformatics in clinical diagnostics is primarily driven by the development of new databases for drug discovery, the use of bioinformatics for clinical diagnostics, and increased funding for the development of bioinformatics solutions for clinical diagnostics, all of which are contributing to the growth of the medical biotechnology segment in the market. Metabolomics is the study of all or a large number of biological metabolites on a global scale. Metabolomics, like other types of functional genomics research, generates a lot of data. Handling, processing, and analyzing this data is a significant undertaking that necessitates the use of sophisticated mathematical, statistical, and bioinformatics software. The Animal Biotechnology segment is predicted to grow with the fastest CAGR of 13.8% in the forecast period 2021-2026. In the veterinary sciences, it has become an essential tool for both basic and applied research. Bioinformatics has advanced veterinary research by introducing new tools for identifying vaccination targets based on the sequencing of biological data from organisms.

Bioinformatics Market Segment Analysis – By Geography

Based on Geography, North America Bioinformatics accounted for the 35% revenue share in 2020. The Bioinformatics Market in this region is growing owing to the government funding for genetic research, the existence of prominent bioinformatics providers, decreasing sequencing prices, improved awareness of bioinformatics services, and an increase in the number of genomic research activities. It has a good funding scenario for research activities. This regional market is characterized by increased government initiatives for genomic testing reimbursement and a favorable financing scenario for bioinformatics research activities. A large number of healthcare investments in the European region is expected to fuel the Bioinformatics Market. Furthermore, the increased adoption of IoT technologies in this industry is likely to have a beneficial impact on regional market growth. With a EUR 20 million investment, the UK government started the COVID-19 Genomics UK Consortium (COG-UK) in March 2020 to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, using whole-genome sequencing (WGS). The NHS, Public Health Agencies, the Wellcome Sanger Institute, and numerous university institutions make up the COVID-19 Genomics UK Consortium (COG-UK).

Bioinformatics Market Drivers

The Occurrence Of Rare Diseases Is Projected To Upsurge Market Growth:

The World Health Organization (WHO) estimates that there are 5,000 to 8,000 different rare diseases in Europe, with 27 million to 36 million people affected. Similarly, new diseases are emerging in other parts of the world that do not yet have a specific prescription treatment. As a result, there is a critical need for novel vaccines and treatments to treat these diseases. These rare diseases, it appears, necessitate a lot of data analytics for diagnosis and treatment, which mostly necessitates bioinformatics and other research methodologies.

The Evolution Of Big Data Technology Is Fueling Bioinformatics Advancement:

Big data has risen to prominence in practically every industry, with a slew of government and private companies using it to boost their bottom lines. In today's world, technology is rapidly evolving, allowing for precise predictive analysis. This steady advancement in big data is fueling the rise of bioinformatics since it allows for a closer examination of current medical issues and the development of new approaches for better treatment.

[marketblogresearch]

DNA Next Generation Sequencing Market Size, Industry Share | Forecast, 2025

The Insight Partners market research DNA Next Generation Sequencing Market Size and Share Report | 2025 is now available for purchase. This report offers an exclusive evaluation of a range of business environment factors impacting market participants. The market information included in this report is assimilated and reliant on a few strategies, for example, PESTLE, Porter's Five, SWOT examination, and market dynamics

DNA Next Generation Sequencing market is evaluated based on current scenarios and future projections are added keeping the projected period in consideration. This report integrates the valuation of DNA Next Generation Sequencing market size for esteem (million USD) and volume (K Units). Research analysts have used top-down, bottom-up, primary, and secondary research approaches to evaluate and approve the DNA Next Generation Sequencing market estimation.

Detailed scrutiny of market shares, optional sources, and basic essential sources has been done to integrate only valid facts. This research further reveals strategies to help companies grow in the DNA Next Generation Sequencing market.

Key objectives of this research are:

To contemporary market dynamics including drivers, challenges, threats, and opportunities in the DNA Next Generation Sequencing market.

To analyze the sum and market estimation of the worldwide DNA Next Generation Sequencing market

Based on key facets, market segments are added.

The competitive analysis covers key market players and their business strategies.

To examine the DNA Next Generation Sequencing Market for business probable and strategic outlook.

To review the DNA Next Generation Sequencing Market size, key regions and countries, end-users, and statistical details.

To offer strategic recommendations based on the latest market developments, and DNA Next Generation Sequencing market trends.

Perks of The Insight Partners’ DNA Next Generation Sequencing Market Research

Market Trends: Our report reveals developing DNA Next Generation Sequencing market trends that are poised to reshape the market preparing businesses with the foresight to retain their competitive edge. This Market research report presents market trends, supply chain analysis, leading participants, and business growth strategies. This research covers technological progress and key developments covering various aspects of the inclusive market. It is valuable market research for existing key players as well as new entrants in the DNA Next Generation Sequencing Market. Through inputs derived from experts, this research attempts to guide future investors about market details and potential returns on investment. 

Competitive Landscape: This research reveals key market players, their strategies, and possible areas for differentiation.

Analysts Viewpoint: We have industry-specific experts who add credibility to this report with their exclusive viewpoints based on market understanding and expertise. This report goes further into details of entire business processes and doesn’t restrict to only operational aspects. These insights cover venture economics and include tactics for capital investment, investor funding, and projections of ROIs.  Net income and profit loss financial stats are crucial metrics of this DNA Next Generation Sequencing market report. With these meticulous insights companies can reduce their risks and increase the success rate in the coming decade. 

DNA Next Generation Sequencing Market Report Coverage:

Report Attributes

Details

Segmental Coverage

By Product

Platforms

Services and Consumables

Application

Diagnostics

Drug Discovery

Precision Medicine

& Other Applications

End User

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Hospitals Clinics

& Other End Users

Geography

North America

Europe

Asia Pacific

and South and Central America

Regional and Country Coverage

North America (US, Canada, Mexico)

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, Australia, Rest of APAC)

South / South & Central America (Brazil, Argentina, Rest of South/South & Central America)

Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)

Market Leaders and Key Company Profiles

Illumina, Inc.

Thermo Fisher

Qiagen N.V.

Beijing Genomics Institute

PerkinElmer, Inc.

Hoffman-La Roche Ltd.

Agilent Technologies

Eurofins Scientific

Oxford Nanopore Technologies Ltd.

Macrogen Inc.

Other key companies 

What all adds up to the credibility of this research?

A comprehensive summary of the contemporary DNA Next Generation Sequencing market scenario

Precise estimations on market revenue forecasts and CAGR to rationalize resources

Regional coverage to uncover new markets for business

Rivalry analysis aims to help corporations at a modest edge

Facts-based crystal-clear insights for business success

The research can be customized as per business necessities

Access to PDF, and PPT formats of this research

 About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: www.theinsightpartners.com

[delvenservices]

Next Generation Sequencing (NGS) Market Outlook, Trends, Size, and Share Analysis

Next Generation Sequencing (NGS) Market analysis report figures out market landscape, brand awareness, latest trends, possible future issues, industry trends and customer behaviour so that the business can stand high in the crowd. It includes extensive research on the current conditions of the industry, potential of the market in the present and the future prospects from various angles. This market report comprises of data that can be pretty essential when it comes to dominating the market or making a mark in the Healthcare industry as a new emergent. To bestow clients with the best results, Next Generation Sequencing (NGS) Market research report is produced by using integrated approaches and latest technology.

Download Free Sample Report at: https://www.delvens.com/get-free-sample/next-generation-sequencing-ngs-market

Next Generation Sequencing (NGS) Market Competitive Landscape:

10X Genomics

Agilent Technologies

BGI Group

Bio-Rad Laboratories Inc.

Brooks Automation Inc.

CD Genomics

DNASTAR Inc.

Eurofins Scientific

F. Hoffmann-La Roche Ltd.

Illumina Inc.

Macrogen Inc.

New England Biolabs

Novogene Corporation Inc.

Oxford Nanopore Technologies

Pacific Biosciences of California Inc.

PerkinElmer Inc.

Precigen Inc., (Intrexon Bioinformatics Germany GmbH)

Promega Corporation

Psomagen

Qiagen

Takara Bio

Tecan Trading Group

Thermo Fisher Scientific Inc.

Zymo Research

Next Generation Sequencing (NGS) Market Recent Developments:

In January, 2023, QIAGEN announced a strategic partnership with California-based population genomics leader Helix to advance next-generation sequencing companion diagnostics in hereditary diseases.

In March, 2023, The company SOPHiA GENETICS announced a new partnership with Qiagen that will pair QIAseq reagent technology with the DDM platform to enhance tumor analysis through next-generation sequencing (NGS).

Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/next-generation-sequencing-ngs-market

The global Next Generation Sequencing (NGS) market size was estimated at USD 11.59 billion in 2023 and is projected to reach USD 29.84 billion in 2030 at a CAGR of 14.47% during the forecast period 2023-2030.

Next-generation sequencing (NGS) is a massively parallel sequencing method that offers scalability, high throughput, and high speed for genome-wide sequencing of nucleotides. Because it involves the preparation of material for the subsequent sequencing reaction, DNA presequencing is one of the most important processes in a common sequencing protocol. Globally, NGS is increasingly integrated into clinical laboratory analysis, testing and disease diagnosis in the healthcare industry. In pharmacogenomics, next-generation sequencing (NGS) is often used to accelerate the drug discovery process.

The growth of the global next-generation sequencing market is primarily driven by the growth of genome mapping programs; proliferation of next-generation sequencing applications; rising health care costs; and technological advances in sequencing platforms. For example, in 2019, Thermo Fisher Scientific, a world leader in scientific services, launched a new generation platform, the Ion Torrent Genexus System, which provides sample for one-day reporting. Additionally, Agilent Technologies, Inc., an American analytical development and manufacturing company, brought in 2019, we launched the Magnis NGS Prep System, a next-generation sequencing library preparation system designed to perform complex sequencing analyzes at the push of a button. Fetal genetic makeup and configuration can be detected with NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT). R&D-related NGS has risen to new heights thanks to investments in NGS technologies worldwide. Growing demand for genome mapping software and increasing use of NGS is fueling market growth.

Scope of the Next Generation Sequencing (NGS) Market Report:

The Next Generation Sequencing (NGS) Market is segmented into various segments such as product, application, technology, end-user and region:

Based on Product

Consumables  

Sample Preparation Consumables  

DNA Fragmentation, End Repair, A-Tailing and Size Selection

Library Preparation & Target Enrichment

Quality Control

Other Consumables  

Platforms

HiSeq

MiSeq

Ion Torrent

Solid

Pacbio Rs II and Sequel System

Other Sequencing Platforms

Services  

Sequencing Services  

RNA Sequencing

Whole Exome Sequencing

Whole Genome Sequencing

Targeted Sequencing

Chip Sequencing

De Novo Sequencing

Methyl Sequencing

Data Management Services  

NGS Data Analysis Services

NGS Data Analysis Software & Workbenches

NGS Storage, Management and Cloud Computing Solutions

Based on Application

Diagnostics

Biomarkers and Cancer

Reproductive Health

Personalized Medicine

Agriculture and Animal Research

Other Applications

Based on the Technology

Sequencing by Synthesis

Ion Semiconductor Sequencing

Sequencing by Ligation

Pyrosequencing

Single Molecule Real Time Sequencing

Other Technologies

Based on End User

Academic and Research Centers

Pharmaceutical and Biotechnology Companies

Hospitals and Clinics

Other End Users

Based on Region

Asia Pacific  

North America  

Europe

South America  

Middle East & Africa  

𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻:

• How economy share fluctuations in their value from different manufacturers?

• Which would important players in the current market and what are their gifts in the total sales development?

• During forecast years which application areas will work well?

• Which global Next Generation Sequencing (NGS) Market trends, challenges, and important competitions of the economy have faced?

• Which are the major final effect and outcomes of the analysis of the advantages of the industry?

For Purchase Enquiry at: https://www.delvens.com/checkout/next-generation-sequencing-ngs-market

Browse Related Reports:

Point of Care Testing Market

Congenital Heart Disease (CHD) Market

Vascular Imaging Market

Magnetic Resonance Imaging (MRI) Coils Market

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[123567-9qaaq9]

Exploring the Frontier: The Global DNA Methylation Detection Technology Market

DNA methylation detection technology stands out as a crucial tool for understanding gene regulation, epigenetics, and disease mechanisms. With advancements in genomics and epigenetics, the global DNA methylation detection technology market has been witnessing remarkable growth, driven by the increasing demand for personalized medicine, precision oncology, and epigenetic research.

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2023 was $2.80 billion, which is expected to reach $12.32 billion by 2023, growing at a CAGR of 15.96%

DNA Methylation Detection Technology Overview 

DNA methylation is an epigenetic mechanism that involves the addition of a methyl group to the DNA molecule, typically at cytosine bases within CpG dinucleotides. This modification plays a pivotal role in regulating gene expression, genomic stability, and cellular differentiation. 

Market Segmentation

Segmentation 1: by Product

Segmentation 2: by Technology

Segmentation 3: by Application

Segmentation 4: by End User

Grab a look at our free sample page click here ! 

Epigenetic Market

The field of epigenetics, which focuses on changes in gene expression that do not involve alterations to the DNA sequence itself, has gained significant attention in recent years for its potential in understanding and treating various diseases. 

Various factors involved are market growth, technological advancements, therapeutic potential

The Epigenetic Market Report forecasts continued expansion of the epigenetic market, fueled by ongoing research advancements, increasing investment in biotechnology and pharmaceutical sectors, and growing adoption of epigenetic-based diagnostics and therapeutics. 

Deoxyribonucleic Acid (DNA) methylation market 

With advancements in next-generation sequencing (NGS) technologies and bioinformatics tools, DNA methylation analysis has become more accessible and cost-effective. The report delves into the latest technological innovations driving market growth, such as whole-genome bisulfite sequencing (WGBS), reduced representation bisulfite sequencing (RRBS), and methylation-specific PCR (MSP).

DNA methylation biomarkers hold immense potential for early disease detection, prognosis, and treatment response prediction across various medical disciplines. The report explores the burgeoning interest in using DNA methylation signatures for cancer diagnosis and monitoring, neurological disorders, cardiovascular diseases, and other pathologies.

Recent Developments in the Global DNA Methylation Detection Technology Market

Pacific Biosciences of California, Inc., and GeneDx initiated a research collaboration with the University of Washington. This partnership focuses on studying the effectiveness of long-read whole genome sequencing in improving diagnostic accuracy in neonatal care. Ultima Genomics, Inc. announced a partnership with New England Biolabs to integrate NEB's NEBNext reagents and library preparation kits into Ultima's sequencing platforms. This collaboration would develop and optimize next-generation sequencing (NGS) processes for DNA, RNA, and methylation sequencing applications.

Key Players 

Agilent Technologies, Inc.

Abcam plc.

Bio-Rad Laboratories, Inc.

Illumina, Inc.

QIAGEN N.V.

Thermo Fisher Scientific, Inc.

And many others 

Visit our Precision medicine page for more understanding! 

Key Questions Answered 

▪ What is the estimated global market size for the global DNA methylation detection technology market? 

▪ Who are the key players in the global DNA methylation detection technology market? 

▪ What are the different types of products available in the global DNA methylation detection technology market? 

▪ Which region holds the largest market share in the global DNA methylation detection technology market? 

▪ How has the COVID-19 outbreak affected the future trajectory of the global DNA methylation detection technology market? 

Conclusion:

The global DNA methylation detection technology market holds immense potential for driving advancements in basic research, clinical diagnostics, and personalized medicine. With ongoing technological innovations, expanding applications, and growing investments in epigenetics research, this market is poised for continued growth and innovation, contributing to our understanding of human health and disease at the molecular level.

[blueweave]

Global Nucleic Acid Isolation and Purification Market size at USD 4.22 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the Global Nucleic Acid Isolation and Purification Market size to expand at a CAGR of 9.23% reaching a value of USD 8.47 billion by 2030. Growing R&D efforts and an increase in the use of sequencing platforms for clinical diagnostics are two key growth drivers for the Global Nucleic Acid Isolation and Purification Market. The is also expected to be driven by an increase in genomics research as well as new product launches.

Opportunity: Rising application for diagnostics

The Global Nucleic Acid Isolation and Purification Market is segmented into drug discovery & development, precision medicine, diagnostics, agriculture and animal research, and other, based on application. The diagnostics segment holds the largest share in the Global Nucleic Acid Isolation and Purification Market. According to research published on ScienceDirect, RNA/DNA genetic tests are the most reliable for identifying infectious illnesses and determining a person's vulnerability to certain diseases, including COVID-19. Drug discovery and development is anticipated to register the highest growth rate during the forecast period.

Impact of Escalating Geopolitical Tensions on Global Nucleic Acid Isolation and Purification Market

The escalating geopolitical tensions restrict the growth of the Global Nucleic Acid Isolation and Purification Market. For instance, Ukraine has been emerging as the leading destination for clinical research and trials of various diseases, particularly cancer. The presence of an organized and digitized health system makes it cheaper to accommodate medical research in Ukraine compared to many other Western European nations. However, Russia’s invasion of Ukraine disrupted the medical research ecosystem in the country. Many reports reveal that Ukraine has a large number of clinical research specialists as well as infrastructure, which directly impacts the demand for nucleic acid isolation and purification, hindering its global market growth.

Sample Request @ https://www.blueweaveconsulting.com/report/nucleic-acid-isolation-and-purification-market/report-sample

[mrfr-blogs]

Understanding the Share Dynamics in Next Generation Sequencing Market

Market Overview –

The next-generation sequencing (NGS) market focuses on providing advanced genomic analysis technologies that enable researchers to sequence and analyze DNA and RNA with unprecedented speed, accuracy, and throughput. NGS technologies have revolutionized genomic research, offering insights into genetic variations, gene expression patterns, and disease mechanisms.

The Next Generation Sequencing (NGS) Market is thriving with the widespread adoption of NGS DNA sequencing technologies. These advanced methods enable rapid and high-throughput sequencing of DNA, driving research and clinical applications. The market offers a range of platforms and services catering to diverse needs, from genomic analysis to personalized medicine, fueling its continuous growth and innovation.

Market growth is driven by several factors, including the increasing adoption of NGS in research and clinical diagnostics, growing demand for personalized medicine, and declining sequencing costs. As NGS becomes more accessible and affordable, there is a growing demand for sequencing services and platforms to support a wide range of applications, from basic research to clinical diagnostics.

Technological advancements and innovations in NGS platforms and bioinformatics tools are shaping the market, offering higher sequencing throughput, improved accuracy, and reduced turnaround times for genomic analysis. From sequencing instruments and reagents to data analysis software and cloud-based solutions, these advancements enhance researchers' ability to generate and interpret large-scale genomic data more efficiently.

Moreover, the expanding applications of NGS in areas such as cancer genomics, infectious disease surveillance, and prenatal screening are driving market growth, as researchers and healthcare providers seek to harness the power of genomics to improve patient care and outcomes. Additionally, the COVID-19 pandemic has accelerated the adoption of NGS technologies for viral genome sequencing and surveillance, highlighting the importance of genomics in understanding and controlling infectious diseases.

However, challenges such as data management, standardization, and regulatory compliance pose obstacles to market growth. Addressing these challenges requires collaboration between NGS technology providers, researchers, regulatory agencies, and healthcare stakeholders to develop standardized protocols, ensure data security, and establish quality assurance measures.

The Next Generation Sequencing Market Size was evaluated at USD 9.46 billion in 2021 and is expected to expand from USD 11.23 billion in 2022 to USD 44.24 billion by 2030, representing a compound yearly growth rate (CAGR) of 18.70% during the forecast period (2022- 2030).

Segmentation –

The global Next Generation Sequencing Market has been segmented based Technology, Workflow and end user.

The next generation sequencing market segmentation, based on technology, includes whole exome sequencing targeted sequencing and resequencing, and whole genome sequencing. Furthermore, targeted sequencing and resequencing bifurcated into DNA-based targeted sequencing & resequencing and RNA-based targeted sequencing & resequencing. The whole exome sequencing segment held the majority share in 2021 contribution to around ~40-42% in respect to the next generation revenue. This is owing to the technological advancements that allow for the rapid sequencing of large amounts of DNA.

The next generation sequencing market segmentation, based on workflow, includes pre-sequencing, sequencing, and data analysis. Furthermore, pre-sequencing has been segmented into NGS library preparation kits, NGS semi-automated library preparation kits, NGS automated library preparation kits, and clonal amplification moreover, data analysis further segmented by type into NGS primary data analysis, NGS secondary data analysis, and NGS tertiary data analysis. The pre-sequencing dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The sequencing is a critical step of the workflow and is a capital-intensive procedure that, in turn, accounts for a higher revenue generation. The last step in the next generation sequencing workflow is processing, analysis, and interpretation of the sequencing data generated.

Based on end user, the Next Generation Sequencing Market has been segmented into hospitals & clinics, diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The diagnostic laboratories segment dominated the market in 2021, while academic & research institutes is projected to be the fastest-growing segment during the forecast period. There are two types of NGS tests for clinical diagnosis, namely, laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Adopting LDTs for routine clinical diagnostics requires ease of use for laboratories and quick turnaround to ensure timely decision-making by clinicians. Both IVDs and LDT are easily reproducible, attainable, reliable, and cost-effective results in the adoption of NGS technology.

Regional Analysis –

The next-generation sequencing (NGS) market displays distinct regional dynamics shaped by factors such as research funding, technological advancements, and regulatory frameworks. North America leads the market, driven by a robust biotechnology sector, extensive research activities, and supportive government initiatives.

The United States accounts for a significant share of NGS adoption, with academic institutions and biotech companies driving innovation. Europe follows closely behind, with countries like the UK, Germany, and France investing in genomic research and personalized medicine initiatives. In the Asia Pacific region, increasing investments in healthcare infrastructure and rising demand for precision medicine contribute to market growth, particularly in countries like China and Japan. Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to funding and infrastructure. Overall, the regional analysis underscores the importance of collaboration between industry stakeholders and policymakers to realize the full potential of NGS technologies in diverse healthcare settings.

Key Players –

Next-generation sequencing major players are Becton Eurofins Scientific based in the US, Illumina, Inc. from the US, Genome Life Sciences headquartered in India, GenScript based in the US, Thermo Fisher Scientific, Inc. also from the US, Qiagen headquartered in Germany, PerkinElmer, Inc. based in the US, F. Hoffmann-La Roche Ltd from Switzerland, Pacific Biosciences of California, Inc. headquartered in the US, Xcelris Genomics from India, along with other participants.

Related Reports –

Diabetic Ulcer Treatment

Medical Tourniquets

Forensic Swab

Ascites

For more information visit at MarketResearchFuture

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[report-1]

Genome Editing Market Size, Type, segmentation, growth and forecast 2023-2030

Genome Editing Market

The Genome Editing Market is expected to grow from USD 5412.80 Million in 2022 to USD 13250.53 Million by 2030, at a CAGR of 18.10% during the forecast period.

Get the Sample Report:https://www.reportprime.com/enquiry/sample-report/11131

Genome Editing Market Size

Genome editing is the process of altering an organism's DNA sequence, typically by cutting and splicing genetic material using engineered nucleases such as CRISPR, TALEN, or ZFN. The market for genome editing is segmented by type, application, region, and key players such as Genscript, Horizon Discovery Group, Lonza, Merck KGaA, Sangamo Therapeutics, and Thermo Fisher Scientific. Applications include cell line engineering, animal genetic engineering, and plant genetic engineering. The market is expected to grow rapidly, driven by increasing demand for precision medicine and research into genetic diseases. However, regulatory and legal factors specific to each market condition will play a critical role in shaping the industry's growth trajectory. Factors like ethical concerns, intellectual property rights, and government regulations will need to be addressed to ensure responsible and sustainable development of genome editing technology.

Genome Editing Market Key Player

Genscript

Horizon Discovery Group

Lonza

Merck KGaA

Sangamo Therapeutics

Buy Now & Get Exclusive Discount on this:https://www.reportprime.com/enquiry/request-discount/11131

Genome Editing Market Segment Analysis

The genome editing market has witnessed significant growth in recent years owing to advancements in technology and growing demand for producing genetically modified organisms (GMOs). The market is expected to grow at a CAGR of 17.2% during the forecast period from 2020 to 2027.

The major factors driving revenue growth for the genome editing market include the growing application of genome editing in therapeutics, research, and agriculture. The increasing demand for non-GMO products has led to the adoption of genome editing technology in agriculture. Moreover, rising investments in gene editing technology and significant funding by governments in research activities are also driving market growth.

The latest trends followed by the genome editing market include the development of CRISPR-based platforms, the increasing use of gene therapy, and the technological advancements in gene editing tools. Researchers are also exploring the application of genome editing in the treatment of genetic disorders such as sickle cell anemia.

However, the genome editing market also faces several challenges such as ethical concerns, regulatory hurdles, and lack of awareness about the potential risks associated with gene editing. Moreover, the high cost of gene editing tools and the limited availability of skilled professionals are hindering the growth of the market.

According to the report, the main findings of the genome editing market include the potential of CRISPR-based platforms and the growing demand for genetically modified crops. Furthermore, the report recommends the need for increased awareness about the risks associated with gene editing and the implementation of appropriate regulations.

In conclusion, the genome editing market is witnessing significant growth owing to the increasing application of gene editing in various industries. However, challenges such as ethical concerns, regulatory hurdles, and limited availability of skilled professionals need to be addressed to ensure sustainable growth. The report's recommendations provide valuable insights for players in the market to overcome these challenges and capitalize on the opportunities presented by the genome editing market.

This report covers impact on COVID-19 and Russia-Ukraine wars in detail.

Purchase This Report:https://www.reportprime.com/checkout?id=11131&price=3590

Market Segmentation (by Application):

CRISPR

TALEN

ZFN

Information is sourced from www.reportprime.com

[shradhacmi]

Global Leukemia Screening Market Is Estimated To Witness High Growth Owing To Technological Advancements

The global Leukemia Screening Market is estimated to be valued at US$17.04 billion in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Leukemia screening is a vital diagnostic tool used for the early detection and monitoring of leukemia, a type of blood cancer. The market for leukemia screening is driven by the increasing prevalence of leukemia worldwide. The advantages of leukemia screening include early detection, accurate diagnosis, and better treatment outcomes. The need for these products is crucial as they help in identifying the disease at an early stage, allowing for timely intervention and improved chances of survival. Market Key Trends: One key trend in the leukemia screening market is the advent of technological advancements in screening techniques. The introduction of innovative technologies such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) has revolutionized the screening process. These advanced techniques offer higher sensitivity, specificity, and accuracy in detecting leukemia cells, leading to more accurate diagnosis and personalized treatment plans. For example, companies like Illumina and Thermo Fisher Scientific Inc. have developed NGS platforms that enable high-throughput sequencing of genomic DNA, providing detailed insights into the genetic alterations associated with leukemia. PEST Analysis: Political: Government initiatives and policies aimed at improving cancer screening programs can positively impact the leukemia screening market. Economic: Increasing healthcare expenditure and rising awareness among individuals about the importance of cancer screening contribute to the market's growth. Social: The growing prevalence of leukemia, especially among the aging population, underscores the need for efficient screening methods. Technological: Technological advancements in molecular diagnostics and genetic testing have significantly enhanced the accuracy and efficiency of leukemia screening. Key Takeaways: 1 - Market size related content: The global leukemia screening market is expected to witness high growth, exhibiting a CAGR of 6.4% over the forecast period, due to increasing awareness about early cancer detection and advancements in screening technologies. For example, the development of liquid biopsy techniques has revolutionized the screening process, allowing for non-invasive detection of Leukemia Screening Market in circulating blood. 2 - Regional analysis related content: North America is expected to dominate the leukemia screening market due to the presence of well-established healthcare infrastructure and increasing investments in cancer research. Asia Pacific is projected to be the fastest-growing region, driven by a rising geriatric population and increased healthcare spending in countries like China and India. 3 - Key players related content: Key players operating in the global leukemia screening market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Illumina, Inc., QIAGEN N.V., Grifols, S.A., Siemens Healthineers AG, Agilent Technologies, Inc., Ortho Clinical Diagnostics, Biocept, Inc., Adaptive Biotechnologies Corporation, Invivoscribe, Inc., and ArcherDX, Inc. These companies focus on product development, collaborations, and mergers to strengthen their market position and expand their product offerings. In conclusion, the global leukemia screening market is experiencing significant growth due to technological advancements in screening techniques. The market's future looks promising, driven by the increasing prevalence of leukemia and the need for early detection to improve patient outcomes. Collaborations among key players and government initiatives to improve cancer screening programs further contribute to the market's expansion.

[delvenservices]

Next Generation Sequencing (NGS) Market Growth Opportunities & Key Players

Next Generation Sequencing (NGS) Market, by Product (Consumables, Platforms, Services and Nerve Blockers), Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Agriculture and Animal Research, and Other Applications), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, and Other Technologies), and End User (Academic and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End Users) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The global Next Generation Sequencing (NGS) market size was estimated at USD 11.59 billion in 2023 and is projected to reach USD 29.84 billion in 2030 at a CAGR of 14.47% during the forecast period 2023-2030.

Next-generation sequencing (NGS) is a massively parallel sequencing method that offers scalability, high throughput, and high speed for genome-wide sequencing of nucleotides. Because it involves the preparation of material for the subsequent sequencing reaction, DNA presequencing is one of the most important processes in a common sequencing protocol. Globally, NGS is increasingly integrated into clinical laboratory analysis, testing and disease diagnosis in the healthcare industry. In pharmacogenomics, next-generation sequencing (NGS) is often used to accelerate the drug discovery process.

The growth of the global next-generation sequencing market is primarily driven by the growth of genome mapping programs; proliferation of next-generation sequencing applications; rising health care costs; and technological advances in sequencing platforms. For example, in 2019, Thermo Fisher Scientific, a world leader in scientific services, launched a new generation platform, the Ion Torrent Genexus System, which provides sample for one-day reporting. Additionally, Agilent Technologies, Inc., an American analytical development and manufacturing company, brought in 2019, we launched the Magnis NGS Prep System, a next-generation sequencing library preparation system designed to perform complex sequencing analyzes at the push of a button. Fetal genetic makeup and configuration can be detected with NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT). R&D-related NGS has risen to new heights thanks to investments in NGS technologies worldwide. Growing demand for genome mapping software and increasing use of NGS is fueling market growth

During the COVID-19 pandemic, governments around the world partnered with the private sector to bring NGS technology to market as a potential diagnostic tool. The NGS diagnostic technique was able to determine the genetic sequence of the virus and helped researchers figure out how mutations occur. Next-generation sequencing (NGS) has been used to study COVID-19, making it much easier to trace the origin of SARS-CoV-2.

To Understand Business Strategies, Request for a Sample Report at: https://www.delvens.com/get-free-sample/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak Declining sequencing costs have increased the use of NGS in disease diagnosis. Various testing kits and testing services are emerging for the non-invasive prenatal testing, cancer diagnosis, genetic testing and more, leading the global market. In addition, active support from the government through product approval and improvement of reimbursements for such diagnostic tests is expected to provide new opportunities for market growth. Additionally, increasing prevalence of chronic diseases, increase in research and initiation of high-budget genomics projects are expected to boost market growth during the forecast period. These factors have led to the expansion of the market and increased demand for Next Generation Sequencing (NGS) solutions.

Key Findings

The application segment is further fragmented into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, agriculture & animal research, and other applications. The biomarker and cancer segment is expected to account for a larger market size during the forecast period due to increase in prevalence of cancer and advancement in technology in next generation sequencing. However, the personalized medicine segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to surge in demand for drug treatment, advancement in R&D in healthcare sector, and rise in awareness for NGS testing in pharmaceutical and biotechnological industry.

The product type segment is further bifurcated into Consumables, Platforms, Services and Nerve Blockers. The consumables segment is the largest market during the forecast period owing to development of technology in molecular genetics and surge in demand for novel pre-sequencing products and kits that execute DNA fragmentation, target enrichment, size selection, and others. However, the services segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to advancement in technology based on SMRT sequencing, and increase in application of cloud computing for NGS data storage.  

The end user segment is further bifurcated into Academic and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End Users. Academic & clinical research to account for a larger market size during the forecast period due to increase in application-based usage in these institutes and rise in oncology research. However, the pharmaceutical & biotechnology companies’ segment is expected to witness considerable market growth during the forecast period, due to increase in prevalence of chronic disease, and advancement in R&D in the next generation sequencing market for therapeutics, oncology, and genomics research.  

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.

Competitive Landscape

10X Genomics

Agilent Technologies

BGI Group

Bio-Rad Laboratories Inc.

Brooks Automation Inc.

CD Genomics

DNASTAR Inc.

Eurofins Scientific

F. Hoffmann-La Roche Ltd.

Illumina Inc.

Macrogen Inc.

New England Biolabs

Novogene Corporation Inc.

Oxford Nanopore Technologies

Pacific Biosciences of California Inc.

PerkinElmer Inc.

Precigen Inc., (Intrexon Bioinformatics Germany GmbH)

Promega Corporation

Psomagen

Qiagen

Takara Bio

Tecan Trading Group

Thermo Fisher Scientific Inc.

Zymo Research

Recent Developments

In January, 2023, QIAGEN announced a strategic partnership with California-based population genomics leader Helix to advance next-generation sequencing companion diagnostics in hereditary diseases.  

In March, 2023, The company SOPHiA GENETICS announced a new partnership with Qiagen that will pair QIAseq reagent technology with the DDM platform to enhance tumor analysis through next-generation sequencing (NGS).

Direct Purchase of Research Report at: https://www.delvens.com/checkout/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.  

Gain authentic and granular data access for the Next Generation Sequencing (NGS) Market to understand the trends and the factors involved in changing market situations.  

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.  

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Next Generation Sequencing (NGS) Market is segmented into various segments such as product, application, technology, end-user and region:

Based on Product

Consumables  

Sample Preparation Consumables  

DNA Fragmentation, End Repair, A-Tailing and Size Selection

Library Preparation & Target Enrichment

Quality Control

Other Consumables  

Platforms

HiSeq

MiSeq

Ion Torrent

Solid

Pacbio Rs II and Sequel System

Other Sequencing Platforms

Services  

Sequencing Services  

RNA Sequencing

Whole Exome Sequencing

Whole Genome Sequencing

Targeted Sequencing

Chip Sequencing

De Novo Sequencing

Methyl Sequencing

Data Management Services  

NGS Data Analysis Services

NGS Data Analysis Software & Workbenches

NGS Storage, Management and Cloud Computing Solutions

Based on Application

Diagnostics

Biomarkers and Cancer

Reproductive Health

Personalized Medicine

Agriculture and Animal Research

Other Applications

Based on the Technology

Sequencing by Synthesis

Ion Semiconductor Sequencing

Sequencing by Ligation

Pyrosequencing

Single Molecule Real Time Sequencing

Other Technologies

Based on End User

Academic and Research Centers

Pharmaceutical and Biotechnology Companies

Hospitals and Clinics

Other End Users

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[desaletushki]

Epigenetics Market Size, Share & Trends Analysis Report, 2030

The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.10% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/epigenetics-market

Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.

Epigenetics Market Report Scope

Report Attribute

Details

Market size value in 2023

USD 14.63 billion

Revenue forecast in 2030

USD 39.15 billion

Growth rate

CAGR of 15.10% from 2023 to 2030

Base year for estimation

2022

Epigenetics Market Report Highlights

By product, the reagents segment accounted for the largest revenue share of 31.50% in 2022 owing to the existence of a number of technology platforms that facilitate analysis at gene, protein, or cellular levels, which encourages innovation in the global marketplace

By application, the oncology segment accounted for the largest revenue share of 69.23% in 2022. The segment is expanding as a result of the increased incidence of cancer and the number of cancer-related fatalities globally

By technology, the histone acetylation segment is anticipated to register the fastest CAGR of 15.8% from 2023 to 2030 due to its improved efficacy as a result of the development of innovative methods

North America dominated the market with the highest revenue share of 38.18% in 2022 owing to government support and increasing R&D funding by government and private organizations

Epigenetics Market Segmentation

Grand View Research has segmented the global epigenetics market report on the basis of product, application, technology, and region:

Epigenetics Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagents

Kits

Chip sequencing kit

Whole Genomic Amplification Kit

Bisulfite Conversion kit

RNA sequencing kit

Others

Instruments

Enzymes

Services

Epigenetics Technology Outlook (Revenue, USD Million, 2018 - 2030)

DNA Methylation

Histone Methylation

Histone Acetylation

Large noncoding RNA

MicroRNA Modification

Chromatin structures

Epigenetics Application Outlook (Revenue, USD Million, 2018 - 2030)

Oncology

Solid Tumors

Liquid Tumors

Non-Oncology

Inflammatory Diseases

Metabolic Diseases

Infectious Diseases

Cardiovascular Diseases

Regional Insights

North America dominated the market with a revenue share of 38.18% in 2022. The large share is mainly attributed to government support and the presence of major companies. High awareness among people, advanced medical infrastructure, and high R&D expenditure are some of the other factors that support the market growth in the region. Moreover, the high prevalence of chronic diseases and increasing investment by market participants for the development of epigenetics will boost regional growth further. For instance, Chroma Medicine, Inc. (Chroma), a brand-new genomic medicine business that pioneered epigenetic editing, started with USD 125 million in investment in November 2021 to treat a variety of disorders and become the most commonly used technology for gene regulation.

The market in the Asia Pacific region is projected to grow at the fastest CAGR of 17.2% from 2023 to 2030. The Asia Pacific market is expected to rise owing to increasing investment in research & development activities by the government and growing incidences of cancer. For instance, in 2022, the WHO South-East Asia Region recorded 1.4 million cancer-related fatalities and approximately 2.2 million new cases, accounting for over one out of every ten deaths in the region. Lung cancer caused 10.6% of cancer-related fatalities, followed by breast cancer (9.4%), cervical cancer (8%), liver cancer (6.6%), and oral cavity cancer at 6.4%. The growing adoption of epigenetics in developing economies will boost regional market growth during the forecast period.

List of Key Players of Epigenetics Market

Roche Diagnostics

Thermo Fisher Scientific, Inc.

Eisai Co. Ltd.

Novartis AG

Element Biosciences, Inc.

Dovetail Genomics LLC.

Illumina, Inc.

ValiRx Plc.

Abcam plc.

 Authoritative Research: https://www.grandviewresearch.com/industry-analysis/epigenetics-market